-The Business Standard Says electronic payments can help manage fraud and leakage risks in government payment programmes The role that technology plays in the economy has become so integral that it can't be ignored, said a recent report by the World Bank. According to the report, electronic payments can save over one per cent of India's gross domestic product (GDP). "Cash may still be king at times, but compared with electronic payments, cash...
More »SEARCH RESULT
Total Matching Records found : 81
A Tough Gangtok Rap -Soumik Dutta
-Outlook An RTI exposes how the Sikkim govt has blatantly misutilised funds meant for quake relief Whose Money Is It Anyway! Of the Rs 60.45 crore allocated for construction of roads and bridges, the state government gave only Rs 30 crore Another Rs 52.64 crore was allocated, of which the government again spent only Rs 3 crore On the other hand, the...
More »UP IAS officer who took on sand mafia suspended -Dipankar Ghose
-The Indian Express Noida (Uttar Pradesh): The Uttar Pradesh government on Sunday suspended an IAS officer who had taken on the sand mafia by clamping down on illegal mining in the Yamuna and Hindon riverbeds over the last few months. Durga Shakti Nagpal, a 2009-batch IAS officer posted as Sub Divisional Magistrate (Sadar) in Gautam Buddh Nagar, had impounded several trucks engaged in illegal quarrying and registered over 20 FIRs. The reason cited...
More »Price control, IP Act & regulatory framework: Revisiting some imp issues about Indian pharma-Ramesh Adige
-The Economic Times Over a year ago, I had written a piece, Quo Vadis, Indian Pharma? (ET, May 11, 2012), in this column. Some key issues were highlighted in the article. Perhaps it is time to revisit the subject and bring out some current issues. Price control: Hurray, the department of pharmaceuticals has come out with a new non-intrusive price control methodology, moving from the cost-based model to the average market price...
More »Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan
-The Times of India NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been "of unacceptable quality". Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable...
More »
